Jane Street Group LLC boosted its position in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 1,390.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 34,399 shares of the medical instruments supplier's stock after buying an additional 32,091 shares during the period. Jane Street Group LLC owned approximately 0.63% of Mesa Laboratories worth $4,536,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of MLAB. Northern Trust Corp boosted its holdings in shares of Mesa Laboratories by 2.0% in the 4th quarter. Northern Trust Corp now owns 93,789 shares of the medical instruments supplier's stock valued at $12,368,000 after acquiring an additional 1,825 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Mesa Laboratories by 12.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,469 shares of the medical instruments supplier's stock worth $458,000 after purchasing an additional 390 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Mesa Laboratories by 72.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,328 shares of the medical instruments supplier's stock valued at $175,000 after buying an additional 560 shares during the last quarter. Herald Investment Management Ltd acquired a new position in shares of Mesa Laboratories in the 4th quarter valued at about $977,000. Finally, XTX Topco Ltd boosted its stake in shares of Mesa Laboratories by 13.3% in the fourth quarter. XTX Topco Ltd now owns 3,382 shares of the medical instruments supplier's stock worth $446,000 after buying an additional 398 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company's stock.
Mesa Laboratories Trading Down 1.6 %
Shares of NASDAQ:MLAB opened at $123.55 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. Mesa Laboratories, Inc. has a 12-month low of $83.68 and a 12-month high of $155.12. The business has a 50 day moving average of $119.23 and a two-hundred day moving average of $126.40. The company has a market capitalization of $671.37 million, a PE ratio of -2.67 and a beta of 0.97.
Mesa Laboratories Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Monday, June 16th. Investors of record on Friday, May 30th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.52%. The ex-dividend date is Friday, May 30th. Mesa Laboratories's dividend payout ratio is currently -1.38%.
Insider Buying and Selling
In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of the company's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the transaction, the chief executive officer now owns 43,337 shares in the company, valued at approximately $5,369,887.67. This represents a 32.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.40% of the stock is currently owned by insiders.
Mesa Laboratories Company Profile
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
Featured Stories
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
